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Summary
Mycoplasmapneumoniae is a common cause of 
respiratory infections. Although most cases are mild, 
some patients have extrapulmonary complications 
including mucocutaneous eruptions including Stevens-
Johnson syndrome (SJS), toxic epidermal necrolysis 
(TEN) and erythemamultiforme (EM). Recently, a new 
entity, called M. pneumoniae-induced rash and mucositis 
(MIRM) was described. The authors present a clinical 
case difficult to classify attending to the classical 
classification of epidermolytic syndromes that meets 
the criteria proposed for the diagnosis of MIRM. The 
mucocutaneous disease associated with M. pneumoniae 
presents predominant mucositis, with scarce or absent 
cutaneous involvement. Because of the distinct 
morphology, pathophysiology and benign clinical course, 
MIRM should be considered as a new entity, distinct 
from SJS/TEN and EM.
Background
Mycoplasma pneumoniae is a well-known cause 
of respiratory infections, but has also been asso-
ciated with extrapulmonary complications.1 In 
fact, studies show that M. pneumoniae can cause 
mucocutaneous eruptions in up to one-quarter of 
all cases.2 The spectrum of dermatological mani-
festations is wide and includes Raynaud’s disease, 
erythema nodosum, Kawasaki disease, erythema 
multiforme (EM), Stevens-Johnson syndrome (SJS) 
and toxic epidermal necrolysis (TEN).1 3 4 Recently, 
Canavan et al have proposed a new entity, distinct 
from SJS/TEN or EM called M. pneumoniae-in-
duced rash and mucositis (MIRM).5
The authors present a case difficult to allocate 
into the classical classification of epidermolytic 
syndromes that meets the criteria proposed by 
Canavan et al for the diagnosis of MIRM.
caSe preSentation
The authors present an otherwise healthy 
8-year-old boy that recurred to the emergency 
service for a 5-day history of dry cough and fever 
(maximum axillary temperature of 39.3°C). A 
chest radiograph showed an ill-defined opacity 
in the left lower lobe (figure 1). The patient was 
diagnosed with atypical pneumonia and treated 
in ambulatory with clarithromycin (15 mg/kg/
day). Over the following 2 days, in addition to 
persistent fever and respiratory complains, the 
patient developed mucocutaneous lesions that led 
to his admission. He took no other medications 
and there was no evidence of previous herpetic 
infection.
The clinical observation revealed painful erosions 
on the lips and oral mucosa partially covered by 
haemorrhagic crusts (figure 2) as well as bilateral 
conjunctival hyperaemia (figure 3). Erythema and 
oedema of the glans penis and prepuce that was 
painful to retract was also found (figure 4). On the 
remaining skin, scattered asymptomatic erythem-
atous papules and atypical target lesions were 
noticed symmetrically on the lower limbs and face 
(figures 2 and 5). The trunk, palms and plants were 
unaffected.
inveStigationS
Blood examinations showed leucocytosis 
(16.1×103 µL) with neutrophilia (78.4%) and 
elevated C reactive protein levels (12.00 mg/L). The 
serum enzyme immunoassay revealed a positive M. 
pneumoniae IgM. Serologic tests for herpes simplex 
virus, cytomegalovirus and Epstein-Barr virus 
yielded negative results.
differential diagnoSiS
Although the mucosal involvement suggested 
SJS, there was a sparse cutaneous involvement. 
That observation allied to the evidence, both clin-
ical and radiological, of atypical pneumonia and 
the increase in M. pneumoniae IgM antibodies 
prompted to the diagnosis of a recently described 
entity of the epidermolytic dermopathies spectrum 
called MIRM.5
There are some key features that may help to 
distinguish MIRM from EM or SJS/TEN: first of 
all, the young age characteristic of most patients 
with MIRM; second, the nosology (evidence of 
atypical pneumonia in MIRM as opposed to the 
herpes simplex virus association of EM and the 
medication aetiology in SJS/TEN); third and 
probably most important, the scarce or absent 
cutaneous involvement in MIRM; and fourth, 
the better prognosis of MIRM even with just 
support treatment.5 6
treatment
Ophthalmological consultation revealed bilateral 
conjunctival hyperaemia and a corneal ulceration 
of the right eye. These ophtalmological findings 
were treated with eye occlusion and topic oxytet-
racycline ointment. Supportive care including 
pain management, intravenous hydration and 
mucosal care (oral suspension of sucralfate 
CASE REpoRT
Mycoplasma pneumoniae-induced rash and 
mucositis: a recently described entity
Rui pedro Santos,1 Marta Silva,2 Ana paula Vieira,3 Celeste Brito4
New disease
to cite: Santos Rp, Silva M, 
Vieira Ap, et al. BMJ Case 
Rep published online First: 
[please include Day Month 
Year]. doi:10.1136/bcr-2017-
220768
1Department of Dermatology 
and Venereology, Hospital de 
Braga, Braga, portugal
2Department of paediatrics, 
Hospital de Braga, Braga, 
portugal
3Department of Dermatology 
and Venereology, Hospital de 
Braga, Braga, portugal
4Department of Dermatology 
and Venereology, Hospital de 
Braga, Braga, portugal
correspondence to
Dr Rui pedro Santos,  
 drruisantos@ hotmail. com
Accepted 5 August 2017
2 Santos Rp, et al. BMJ Case Rep 2017. doi:10.1136/bcr-2017-220768
new disease
for oral mucosa and an ointment containing prednisolone 
acetate, neomycin sulfate and sodium sulfacetamide for the 
genital lesions) was also administered.
The patient was treated with intravenous immunoglobulins at 
a dosage of 1 g/kg/day for 3 days with a rapid improvement in 
the ocular, oral and urinary symptoms as well as the skin lesions.
outcome and follow-up
The patient was discharged after 8 days with noticeable clinical 
improvement (figure 6).
diScuSSion
The classical classification of epidermolytic dermopathies that 
encompassed EM (minor and major), SJS and TEN as part of 
a spectrum of disease has been updated, when, in 1993 Bastu-
ji-Garin et al proposed a novel classification: EM as a different 
entity from SJS/TEN, with its own aetiology, pathophysiology 
and clinical course.7 Since then, another update was achieved, 
when, in 2013 the drug reaction with eosinophilia and systemic 
symptoms syndrome was recognised as a separate entity, outside 
the SJS spectrum.8
Recently, another breakthrough in this area was made by 
Canavan et al, in 2015, by describing a new syndrome called 
MIRM.5 This new entity helps to classify several cases with 
mucosal findings consistent with SJS, but without (or scarce) 
cutaneous involvement, preceded by a recognised M. pneumo-
niae infection. These cases have been classified as ‘atypical’ or 
‘incomplete SJS’ but also as ‘Fuchs syndrome’.5
M. pneumoniae is the most common infectious agent asso-
ciated with acute epidermolytic dermopathies, particularly in 
children.6 Mucocutaneous eruptions associated with M. pneu-
moniae infection are more often characterised by moderate to 
severe involvement of two or more mucosal sites and sparse or 
even absent skin involvement. However, it is uncertain whether 
M. pneumoniae-associated mucositis with minimal or no skin 
involvement represents an atypical SJS variant or is a distinct 
entity as proposed by Canavan et al.5 6 9 10
In the study performed by Canavan et al, 202 cases compat-
ible with MIRM were found with a male preponderance and 
a markedly young age (mean 11.9 years old).5 All patients had 
prodromal symptoms (cough, fever, malaise) the week prior to 
the eruption.5 MIRM has a pleomorphic presentation, but the 
most common morphologies are vesiculobullous (77%), targe-
toid lesions (48%), papules (14%) and macules (12%).5 The 
cutaneous involvement is sparse (a few scattered lesions) in about 
figure 1 Chest radiograph: note the ill-defined opacity in the left 
lower lobe.
figure 2 Erosions on the lips and oral mucosa partially covered by 
haemorrhagic crusts. Also note some atypical targets with central bulla 
on the face.
figure 3 Conjunctival hyperaemia.
figure 4 Erythema and oedema of the glans penis and prepuce.
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half the cases or absent (MIRM sine rash) in one-third of cases.5 
When present, the cutaneous lesions have a predominantly acral 
distribution, but the trunk and face can also be affected.5 The 
mucosal involvement is critical to the diagnosis, with a mean 
of 2.5 mucosal sites affected. The oral mucosa is affected in the 
vast majority of cases (94%, varying from isolated erosions to 
significant denudation of the entire buccal mucosa), followed 
by the ocular mucosa (82%, with purulent bilateral conjunc-
tivitis and photophobia) and the genital mucosa (63%, with 
vesiculobullous and ulcerations).5 There are no guidelines for 
the treatment of MIRM.5 11 12 The majority of cases are treated 
with antibiotics, systemic corticosteroids, intravenous immu-
noglobulin, supportive care or a combination of the above.5 
MIRM seems to have an overall good prognosis as the majority 
of patients recover without sequels and the recurrences are rare 
(8%).5 Among the possible complications the most common are 
synechiae (ocular, oral and genital).13 Rare complications do 
sometimes occur as persistent cutaneous lesions or B-cell lymph-
opaenia.13 A 3% of fatalities due to pulmonary complications 
has been published, but these cases (a total of four) refer to a 
preantibiotic era and therefore does not affect the actual good 
prognosis of the disease.5
The aetiopathophysiology of MIRM is still unclear, but may 
be distinct from EM or SJS/TEN. EM is strongly associated 
with herpes simplex virus and SJS/TEN is traditionally linked 
to medication exposure (despite other possible causes, including 
M. pneumoniae infection). MIRM is associated with M. pneu-
moniae infection. It was hypothesised that antibody production, 
immunocomplex deposition and complement activation would 
result in mucocutaneous damage.2 Molecular mimicry between 
Mycoplasma adhesion molecules and a keratinocyte antigen is 
also a hypothesis.14 15 This proposed pathophysiology is clearly 
different from EM and SJS/TEN that likely involves a type IV 
delayed-type hypersensitivity reaction and cytotoxicity due to a 
Fas-ligand mechanism.16–19
Canavan et al propose a set of diagnostic criteria for cases of 
MIRM.5 This encompasses skin detachment of less than 10% of 
the body surface area, at least two mucosal sites involved, few skin 
lesions including vesiculobullous or atypical targets and evidence of 
atypical pneumonia (clinical and laboratorial).5 It should be empha-
sised the importance of definitive M. pneumoniae identification 
to the correct diagnosis of MIRM and even more to differentiate 
from herpes simplex virus-associated EM and drug-associated SJS/
TEN.5 20 Our patient met most of this criteria as he was diagnosed 
with atypical pneumonia, had positive IgM antibodies for M. pneu-
moniae, had three affected mucosal sites (ocular, oral and genital) 
and a few scattered atypical targets on the skin. Also the favourable 
clinical evolution and good outcome is in accordance with the diag-
nosis.
Attending to the methodic study of Canavan et al, demonstrating 
MIRM as a separate entity due to the young age of patients, 
predominance (or only) mucosal involvement and excellent prog-
nosis we highlight the usefulness of this diagnosis to the classifica-
tion of this case. Previously, a patient like ours, with predominant 
mucosal involvement but scarce or none cutaneous findings was 
difficult to classify and if so, was probably termed as ‘incomplete’ 
SJS. However, SJS, even ‘incomplete’, has a far worse prognosis 
than MIRM and so an accurate diagnosis is of critical importance 
for the correct management and prognosis.
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figure 5 Scattered erythematous papules and atypical targets 
symmetrically distributed on the lower limbs.
figure 6 Clinical improvement of the cutaneous and mucosal lesions 
at discharge.
learning points
 ► Mycoplasma pneumoniae can cause mucocutaneous 
eruptions, including a new entity from the epidermolytic 
dermopathies spectrum, called M. pneumoniae-induced rash 
and mucositis (MIRM).
 ► The mucocutaneous disease associated with M. pneumoniae 
presents predominant mucositis, with scarce or absent 
cutaneous involvement.
 ► The aetiopathophysiology of MIRM is still unclear, but may 
be distinct from erythema multiforme or Stevens-Johnson 
syndrome/toxic epidermal necrolysis.
 ► The majority of cases are treated with antibiotics, systemic 
corticosteroids, intravenous immunoglobulins and supportive 
care.
 ► MIRM has an overall good prognosis as the majority of 
patients recover without sequels and the recurrences are 
rare.
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